- Home
- MDB vs WAT Comparison
MDB vs WAT Comparison
Compare MDB & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDB
- WAT
- Stock Information
- Founded
- MDB 2007
- WAT 1958
- Country
- MDB United States
- WAT United States
- Employees
- MDB N/A
- WAT N/A
- Industry
- MDB Computer Software: Prepackaged Software
- WAT Biotechnology: Laboratory Analytical Instruments
- Sector
- MDB Technology
- WAT Industrials
- Exchange
- MDB Nasdaq
- WAT Nasdaq
- Market Cap
- MDB 15.8B
- WAT 17.4B
- IPO Year
- MDB 2017
- WAT 1995
- Fundamental
- Price
- MDB $377.56
- WAT $378.00
- Analyst Decision
- MDB Strong Buy
- WAT Buy
- Analyst Count
- MDB 36
- WAT 13
- Target Price
- MDB $356.44
- WAT $379.00
- AVG Volume (30 Days)
- MDB 1.6M
- WAT 657.2K
- Earning Date
- MDB 12-01-2025
- WAT 11-04-2025
- Dividend Yield
- MDB N/A
- WAT N/A
- EPS Growth
- MDB N/A
- WAT 3.82
- EPS
- MDB N/A
- WAT 10.88
- Revenue
- MDB $2,218,189,000.00
- WAT $3,105,638,000.00
- Revenue This Year
- MDB $18.67
- WAT $7.12
- Revenue Next Year
- MDB $17.01
- WAT $6.22
- P/E Ratio
- MDB N/A
- WAT $34.80
- Revenue Growth
- MDB 21.91
- WAT 6.90
- 52 Week Low
- MDB $140.78
- WAT $275.05
- 52 Week High
- MDB $385.44
- WAT $423.56
- Technical
- Relative Strength Index (RSI)
- MDB 71.09
- WAT 74.17
- Support Level
- MDB $339.00
- WAT $340.09
- Resistance Level
- MDB $365.86
- WAT $382.02
- Average True Range (ATR)
- MDB 14.77
- WAT 10.45
- MACD
- MDB 2.31
- WAT 1.74
- Stochastic Oscillator
- MDB 87.62
- WAT 92.26
About MDB MongoDB Inc.
Founded in 2007, MongoDB is a vendor of a document-oriented database that accelerates development processes of new applications. Enterprise customers can choose between the fully managed offering, MongoDB Atlas, or the self-managed version, MongoDB Enterprise Advanced. MongoDB is a popular tool among developers, and its free Community Server has recorded over 500 million downloads since 2009.
About WAT Waters Corporation
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.